戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  Epstein-Barr virus (EBV) infection, such as lymphomatoid granulomatosis (LG) or post-transplant lymp
2                                              Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr
3                                              Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr
4                                              Lymphomatoid granulomatosis (LyG) is an angiodestructive
5 lfa-2b is efficacious for treating low-grade lymphomatoid granulomatosis and hence reducing progressi
6 crosis and vascular damage from EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/na
7 mally elevated in patients with EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/NK
8 er with untreated, or relapsed or refractory lymphomatoid granulomatosis at the National Cancer Insti
9                                              Lymphomatoid granulomatosis has a high rate of central n
10                                              Lymphomatoid granulomatosis is a rare Epstein-Barr virus
11 n this study, we hypothesised that low-grade lymphomatoid granulomatosis is immune-dependent and high
12 lomatosis is immune-dependent and high-grade lymphomatoid granulomatosis is immune-independent.
13 de disease, whereas patients with high-grade lymphomatoid granulomatosis showed expected responses to
14 , and he had a biopsy-confirmed diagnosis of lymphomatoid granulomatosis that evolved into fatal B-ce
15 y-one patients with pathologically confirmed lymphomatoid granulomatosis were enrolled in a natural h
16 monary T- or NK-cell angiocentric lymphomas (lymphomatoid granulomatosis), 12/19 T-cell anaplastic la
17 n remission, and one with toxoplasmosis plus lymphomatoid granulomatosis).
18 ma closely mimics the full spectrum of human lymphomatoid granulomatosis, an EBV-associated malignanc
19 n of central nervous system involvement from lymphomatoid granulomatosis.
20 t this translocation at the genomic level in lymphomatoid papulosis (14 cases), primary cutaneous CD3
21              Lesional DNA from patients with lymphomatoid papulosis (fourteen cases), Hodgkin's disea
22 ression of skin lesions is characteristic of lymphomatoid papulosis (LyP), a clonal cutaneous lymphop
23 phoproliferative disorders (LPDs), including lymphomatoid papulosis (LyP), anaplastic and nonanaplast
24 was undertaken to determine the clonality of lymphomatoid papulosis (LyP), its clonal relationship to
25     Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplast
26 t for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no app
27                            All patients with lymphomatoid papulosis (n = 9) and primary cutaneous ana
28 0 ligand expression in regressing lesions of lymphomatoid papulosis and cutaneous CD30+ anaplastic la
29 he large-cell lymphoma cases, and six of the lymphomatoid papulosis cases were then subjected to dot
30                                              Lymphomatoid papulosis is part of a spectrum of CD30+ cu
31 ne were found in the six additional cases of lymphomatoid papulosis that were studied.
32 mors of two patients who had progressed from lymphomatoid papulosis to systemic anaplastic large cell
33                       Hodgkin's disease, and lymphomatoid papulosis, and to establish the usefulness
34 tions have also been made in the sections on lymphomatoid papulosis, increasing the spectrum of histo
35 btained from 16 patients with MF, seven with lymphomatoid papulosis, seven with primary cutaneous CD3
36 ther tumors, including Hodgkin's disease and lymphomatoid papulosis, were ALK1-.
37 l tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an overall response rate of
38 t not in any patients with other NHL, HD, or lymphomatoid papulosis.
39 , 31 with Hodgkin's disease (HD), and 6 with lymphomatoid papulosis.